The Relationship between Telomere Length and Telomerase Activity in Gynecologic Cancers

doi:10.1006/gyno.2001.6483

Gynecologic Oncology

Volume 84, Issue 1, January 2002, Pages 81-84

https://doi.org/10.1006/gyno.2001.6483 Get rights and content

Abstract

Objective. In recent years, many studies have been published regarding telomere length and telomerase activity in malignant tissues. However, it is not enough that telomere length and telomerase activity in gynecologic cancers have been measured at same time. We investigated the relationship between telomere length and telomerase activity in gynecologic cancers.

Methods. A total of 52 gynecologic cancers (15 ovarian cancers, 23 endometrial cancers, 14 cervical cancers) were obtained at the time of surgery. The specimens were analyzed for telomerase activity and telomere length with the TRAP_EZE ELISA kit and Southern blot, respectively.

Results. Telomerase activity was detected in 42 of 50 (84.0%) of all evaluable specimens, in 11/15 (73.3%) ovarian, 18/22 (81.8%) endometrial, and in 13/13 (100%) cervical cancers. The difference of positive strength (ΔA value) between stage I and III was statistically significant (P = 0.01, ANOVA test). Changes in telomere length by shortening or elongation were detected in 35 of 52 (67.3%) tumors, in 9/15 (60.0%) ovarian, 17/23 (73.9%) endometrial, and 9/14 (64.3%) cervical cancers. There was no detectable relationship between telomere length and stage of disease, pathologic diagnosis (ovarian, endometrial, and cervical cancers), or telomerase activity.

Conclusions. There was no relationship between telomerase activity and telomere length. The clinical significance of telomere length appears to be limited in gynecologic cancers.

References (28)

T Kitada et al.
Telomere shortening in chronic liver diseases
Biochem Biophys Res Commun
(1995)
G Bonatz et al.
Telomere shortening in uterine leiomyomas
Am J Obstet Gynecol
(1998)
GB Morin
The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats
Cell
(1989)
Y Shirotani et al.
Alteration in length of telomeric repeats in lung cancer
Lung Cancer
(1994)
JW Shay et al.
A survey of telomerase activity in human cancer
Eur J Cancer
(1997)
CM Counter et al.
Telomerase activity in normal leukocytes and in hematologic malignancies
Blood
(1995)
AM Burger et al.
Inhibition of telomerase activity by cisplatin in human testicular cancer cells
Eur J Cancer
(1997)
RC Allshire et al.
Human telomeres contain at least three types of G-rice repeat distributed non-randomly
Nucleic Acids Res
(1989)
ND Hastie et al.
Telomere reduction in human colorectal carcinoma and with aging
Nature
(1990)
O Yamada et al.
Telomere reduction in hematologic cells
Int J Hematol
(1993)

CB Harley et al.

Telomerase, cell immortality, and cancer

Cold Spring Harb Symp Quant Biol

(1994)

VA Zakian

Structure and function of telomeres

Annu Rev Genet

(1989)

P Nurnberg et al.

Changes of telomere lengths in human intracranial tumours

Hum Genet

(1993)

Cited by (23)

Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients
2015, Molecular Oncology
Citation Excerpt :
Our data show that telomere shortening can be extensive in breast tumours, yet this appears to occur in the presence of telomerase, which is detected in the majority of breast tumours analysed (Hiyama et al., 1996; Pearson et al., 1998). However an absence of any relationship between the levels of telomerase activity and telomere length has been reported in Breast cancer (Lu et al., 2011) and other tumour types (Wang et al., 2002). We have recently shown that short telomeres can be detected in early stage lesions for example in colorectal adenomatous polyps (Roger et al., 2013) and in chronic lymphocytic leukaemia prior to clinical progression (Lin et al., 2010, 2014).
Telomere dysfunction and fusion can drive genomic instability and clonal evolution in human tumours, including breast cancer. Telomere length is a critical determinant of telomere function and has been evaluated as a prognostic marker in several tumour types, but it has yet to be used in the clinical setting. Here we show that high-resolution telomere length analysis, together with a specific telomere fusion threshold, is highly prognostic for overall survival in a cohort of patients diagnosed with invasive ductal carcinoma of the breast (n = 120). The telomere fusion threshold defined a small subset of patients with an extremely poor clinical outcome, with a median survival of less than 12 months (HR = 21.4 (7.9–57.6), P < 0.0001). Furthermore, this telomere length threshold was independent of ER, PGR, HER2 status, NPI, or grade and was the dominant variable in multivariate analysis. We conclude that the fusogenic telomere length threshold provides a powerful, independent prognostic marker with clinical utility in breast cancer. Larger prospective studies are now required to determine the optimal way to incorporate high-resolution telomere length analysis into multivariate prognostic algorithms for patients diagnosed with breast cancer.
Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women
2011, Annals of Oncology
Citation Excerpt :
Thus, cyclic withdrawal of progestin, rather than continuous therapy, has been proposed as an alternative strategy for patient treatment [31]. The receptors themselves are not the sole participants in this process, however, as the response to treatment with progestin may be further modified by tumor-specific perturbations of the downstream cellular apoptotic signaling pathways [31]. Uterus-sparing hormonal treatment of AEH and well-differentiated carcinoma with a combination of injected GnRH analogue and progestin-impregnated IUD can be effective in some patients.
To test the efficacy of levonorgestrel-release intrauterine device (LNG-IUD) plus gonadotropin-releasing hormone (GnRH) for treating women aged <40 years with atypical endometrial hyperplasia (AEH) or presumed International Federation of Gynecology and Obstetrics stage IA limited to the endometrium, well differentiated (G1), endometrioid endometrial cancer (EC), who wish to preserve their fertility.
A prospective observational study was conducted. Treatment consisted on the insertion of an LNG-IUD for 1 year plus GnRH analogue for 6 months.
From January 1996 to June 2009, 20 and 14 patients with AEH and EC, respectively, were studied. Complete response rate was 95% in patients with AEH and 57.1% in women with EC-G1. A progression of the disease was observed in one (5%) and in four patients (28%) with AEH and EC, respectively. Four of 20 patients with AEH and 2 of 14 with EC-G1 experienced recurrences. The average relapse time was 36 months (range: 16–62 months). All of them were alive without evidence of disease at the last follow-up, mean: 29 months (range: 4–102 months). Nine women achieved 11 spontaneous pregnancies.
The combined treatment showed effectiveness in a substantial proportion of patients with AEH and EC. Close follow-up during and after treatment is crucial.
Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP
2010, European Journal of Pharmacology
We have previously shown that PMEG diphosphate (PMEGpp) and PMEDAP diphosphate (PMEDAPpp) inhibit the enzymatic activity of human telomerase in a cell-free assay. Here, we investigated the ability of PMEG and PMEDAP to induce telomere shortening and telomerase inhibition at both transcriptional and activity level in T-lymphoblastic leukemia cells CCRF-CEM and MOLT-4. At defined time points (3 days and 9 weeks), the telomerase activity and relative levels of hTERT and c-myc mRNA were determined using real-time RT-PCR. Telomere length was measured by the flow-FISH method. Both PMEDAP and PMEG induced telomere shortening in CCRF-CEM cells after 9 weeks of exposure by 50% and 20%, respectively, without major impairment of telomerase activity. The effect of the tested compounds on telomere length in MOLT-4 cells was the opposite, with telomere elongation by 50% and 40% after 9-week treatment with PMEDAP and PMEG, respectively. At this time point, telomerase activity in MOLT-4 cells appeared to be slightly higher than that of CCRF-CEM cells, nevertheless no correlation between telomerase activity and telomere length was found. Both compounds down-regulated the expression of hTERT and c-myc mRNA in CCRF-CEM and MOLT-4 cells at 72 h in a concentration-dependent manner while prolonged exposure to PMEG or PMEDAP for 9 weeks had weaker effects. In conclusion, PMEDAP and PMEG are able to modulate telomere length in leukemic cells and this effect is cell-type specific. It is neither due to direct telomerase inhibition nor impairment of hTERT expression and it is likely to be telomerase-independent.
Inhibition of 6A8 α-mannosidase gene expression resulted in telomere length shortening in nasopharyngeal carcinoma cell CNE-2L2
2005, Cancer Letters
Telomere length shortening was observed in the nasopharyngeal carcinoma cell CNE-2L2 when 6A8 α-mannosidase expression was inhibited by antisense 6A8 DNA. Transduction with mock or an irrelevant DNA did not affect the telomere length in the carcinoma cells. Telomerase activity and mRNA transcription of TRF 1 and 2 were not changed in the cells treated with antisense 6A8. The Con A binding test showed an enhancement on the proteins isolated from the cells treated with antisense 6A8, but not on those from mock- or irrelevant DNA-treated cells. The data imply an association between glycosylation modification with telomere shortening in antisense 6A8-treated cells.
Speculation and Deductive Reasoning About Ovarian Epithelial Carcinogenesis and New Horizons
2003, Diagnosis and Management of Ovarian Disorders, Second Edition
Deductive reasoning may give insight into why cancer forms in inclusion cysts, the unappreciated role of the stroma, the 10- to 40-year time for cancer to develop, why the psammoma body might be the remnants of wayward cells, the myth of the “evil genius” cancer, why most intraperitoneal metastases are superficial, the mechanisms of multifocal peritoneal carcinomatosis, and a reason for recurrence after a negative “second look.”
Recommendations are suggested for improved researcher communication, verifying the diagnosis of dysplasia, coordinating the bits and pieces of genetic findings, improving ultrasound resolution and serum tumor markers, chemoprevention, and prophylactic salpingo-oophorectomy rather than oophorectomy.
Aberrant dyskerin expression is related to proliferation and poor survival in endometrial cancer
2021, Cancers

View all citing articles on Scopus

¹: To whom correspondence and reprint requests should be addressed at Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan. Fax: 00-81-282-86-6856. E-mail: [email protected].

View full text

Regular ArticleThe Relationship between Telomere Length and Telomerase Activity in Gynecologic Cancers

Abstract

Biochem Biophys Res Commun

Am J Obstet Gynecol

Cell

Lung Cancer

Eur J Cancer

Blood

Eur J Cancer

Human telomeres contain at least three types of G-rice repeat distributed non-randomly

Nucleic Acids Res

Telomere reduction in human colorectal carcinoma and with aging

Nature

Telomere reduction in hematologic cells

Int J Hematol